The intravascular persistence and methemoglobin formation of Hemolink™ (Hemoglobin raffimer) in dogs

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology

Volumn 31, Issue 1, 2003, Pages 1-17

  Wicks, David ^a   Wong, Lawrence T ^a   Sandhu, Reena ^a,c   Stewart, Richard K ^b,d   Biro, George P ^a  

^a Hemosol Inc   (Canada)

^b ITR Laboratories Canada Inc   (Canada)

^c Apotex Research Inc   (Canada)

^d CATO RESEARCH LTD   (United States)

Author keywords

Half life; Heme iron oxidation; Hemoglobin raffimer; Hemoglobin solution; Intravascular persistence; Methemoglobin formation; Modified hemoglobin solution; Oxygen therapeutic; Plasma hemoglobin; Red cell substitute

Indexed keywords

CELLS; CROSSLINKING; HEMOGLOBIN; MOLECULAR WEIGHT; OLIGOMERS;

PLASMA HEMOGLOBIN;

BIOTECHNOLOGY;

BLOOD SUBSTITUTE; HEMOGLOBIN; METHEMOGLOBIN; OLIGOMER; RAFFINOSE; TETRAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; BLOOD VOLUME; DOG; GEL PERMEATION CHROMATOGRAPHY; HALF LIFE TIME; HEMOGLOBIN SYNTHESIS; MOLECULAR WEIGHT; NONHUMAN; OXIDATION;

ANIMALS; BLOOD SUBSTITUTES; DOGS; HALF-LIFE; HEMOGLOBINS; METABOLIC CLEARANCE RATE; METHEMOGLOBIN; MOLECULAR WEIGHT; OXIDATION-REDUCTION; RAFFINOSE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0037278156     PISSN: 10731199     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIO-120018000     Document Type: Article

References (12)

1. Brooks, J. (1935). The oxidation of haemoglobin to methaemoglobin by oxygen II - The relation between the rate of oxidation and the partial pressure of oxygen. Proc. R. Soc. Lond. 547:560-577.
2. Carmichael, F. J., Ali, A. C., Campbel, J. A., Langlois, S. F., Biro, G. P., Willan, A. R., Pierce, C. H., Greenburg, A. G. (2000). A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit. Care Med. 28:2283-2292.
3. Caron, A., Menu, P., Faivre-Fiorina, B., Labrude, P., Alayash, A., Vigneron, C. (2000). Systemic and renal hemodynamics after moderate hemodilution with HbOCs in anesthetized rabbits. Am. J. Physiol. Heart Circ. Physiol. 278: H1974-H1983.
4. Cohn, S. M. (2002). Oxygen therapeutics in trauma and surgery. J. Trauma, in press.
5. Faivre, B., Menu, P., Labrude, P., Vigneron, C. (1994). Do the dissociation of the dex-BTC-Hb and its oxidation influence the P50 in vivo in guinea pig? Art. Cells Blood Substit. Immobil. Biotechnol. 22:A97.
6. Guidiotti, G. (1967). Studies on the chemistry of hemoglobin. J. Biol. Chem. 242:3685-3693.
7. Lee, R., Neya, K., Svizzero, T. A., Vlahakes, G. J. (1995). Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J. Appl. Physiol. 79(1):236-242.
8. McGown, E. L., Lyons, M., Zegna, A. (1990). Reduction of extracellular methemoglobin by erythrocytes. Biochim. Biophys. Acta 1036:202- 206.
9. Neya, K., Lee, R., Vlahakes, G. J. (1998). Hemoglobin based oxygen carrying solution stability in extracorporeal circulation: an in vitro evaluation and implications for clinical use. ASAIO J. 44(3):166-170.
10. Ning, J., Er, S. S., Wong, L. T. (1998). In vivo oxygenation of deoxy-HEMOLINK™ 50% or 90% the blood volume in rats. In: Tsuchida, E., ed. Blood Substitutes - Present and Future Perspectives. New York: Elsevier Science, pp. 211-223.
11. Scott, E. M., Duncan, I. W., Ekstrand, V. (1965). The reduced pyridine nucleotide dehydrogenases of human erythrocytes. J. Biol. Chem. 240:481-485.
12. Sprung, J., Kindscher, J., Wahr, J. A., Levy, J. H., Monk, T. G., Moritz, M. W., O'Hara, P. J. (2002). The use of bovine hemoglobin glutamer-250 (Hemopure®) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth. Analg. 94:799-808.